Eolas faoin údar
Šarūnas Narbutas
Co-founder & Chairman, Youth Cancer Europe · Chief Advisor, Lithuanian Cancer Patient Coalition (POLA) · Community Advisory Board member, CML Advocates Network
Life Sciences lawyer, LL.M (Vilnius University Faculty of Law) · Stanford GSB Executive Education alumnus · EUPATI Fellow · Patient Expert · Chronic myeloid leukaemia survivor · Co-author of peer-reviewed work in Leukemia, HemaSphere, Molecular Oncology and Frontiers in Pharmacology
Šarūnas Narbutas reviews beatcancer.eu articles for accuracy from a patient-advocacy, legal and health-policy perspective. Diagnosed with chronic myeloid leukaemia at 18, he launched a national petition signed by about 180,000 people, roughly 6% of Lithuania's population, which secured reimbursement of modern CML therapy. He served on the Board of the European Cancer Patient Coalition (ECPC) from 2010 to 2013 and led the Lithuanian Cancer Patient Coalition (POLA) for over a decade, first as President and now as Chief Advisor. He co-founded Youth Cancer Europe, the pan-European network for young people affected by cancer, which he chairs. From 2017 to 2022 he chaired the CML Advocates Network, the global community of leukaemia patient groups, and he now sits on its community advisory board. He is a Life Sciences lawyer by training, with a master's degree in International and EU Law from Vilnius University, where he later lectured on health law, EU law and public international law. He served as legal adviser to the President of the Republic of Lithuania, has been a member of the Ministry of Health's Advisory Board, a member of reimbursement committee, deputy chair of the commission awarding damages for medical malpractice, Chairman of the Governmental Fund on the Promotion of Public Health and, member of the National Health Council, board member at Invest Lithuania, responsible for Life Sciences sector. He has also advised World Health Organization, the OECD and the European Commission. He completed the STERN Leadership Academy at Stanford Graduate School of Business Executive Education (2024) and is a EUPATI Fellow, a graduate of the first Patient Expert Training Course of the European Patients' Academy on Therapeutic Innovation (2014 to 2015). A member of the EFPIA Patient Think Tank since 2016, he led the legal drafting of the WECAN Guiding Principles on Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (2018) and was one of the principal authors of PFMD's fair-market-value principles for patient engagement (2021 to 2022). He has led work packages and tasks in more than ten EU-funded projects under Horizon Europe, EU4Health and the Innovative Health Initiative. His published work includes the European Cancer Organisation's Essential Requirements for Quality Cancer Care in haematological malignancies (HemaSphere, 2025), patient-reported outcomes from the phase 3 ASCEMBL trial (Leukemia, 2023), recommendations on embedding survivorship research in the EU Cancer Mission (Molecular Oncology, 2021) and joint patient-physician guidance on treatment-free remission in CML. He brings lived experience of cancer, legal and policy expertise, and an evidence-first approach to every review.























